Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Current Leases (2019 - 2025)

Historic Current Leases for Sanofi (SNY) over the last 7 years, with Q4 2025 value amounting to $316.6 million.

  • Sanofi's Current Leases rose 1353.34% to $316.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $316.6 million, marking a year-over-year increase of 1353.34%. This contributed to the annual value of $307.4 million for FY2025, which is 881.36% up from last year.
  • According to the latest figures from Q4 2025, Sanofi's Current Leases is $316.6 million, which was up 1353.34% from $285.3 million recorded in Q2 2025.
  • In the past 5 years, Sanofi's Current Leases registered a high of $316.6 million during Q4 2025, and its lowest value of $246.5 million during Q2 2022.
  • Its 5-year average for Current Leases is $288.7 million, with a median of $290.6 million in 2023.
  • In the last 5 years, Sanofi's Current Leases plummeted by 1713.37% in 2022 and then soared by 1353.34% in 2025.
  • Sanofi's Current Leases (Quarter) stood at $307.7 million in 2021, then decreased by 8.16% to $282.6 million in 2022, then grew by 4.7% to $295.9 million in 2023, then dropped by 5.74% to $278.9 million in 2024, then rose by 13.53% to $316.6 million in 2025.
  • Its Current Leases was $316.6 million in Q4 2025, compared to $285.3 million in Q2 2025 and $278.9 million in Q4 2024.